Public and Private Offerings

• Belite Bio, Inc (NASDAQ: BLTE) in:
• US$36 million IPO and listing on NASDAQ
• US$30 million follow-on offering
• US$15 million registered direct offering of ADSs and warrants to a single institutional investor
• upsized US$275 million private placement financing
• US$350 million underwritten public offering
• Sunho Biologics in Approximately US$60 Million IPO and listing on the Hong Kong Stock Exchange
• eHi Car Services Limited in:
• US$120 million IPO and listing on the NYSE
• US$325 million Regulation S high-yield bond offering due 2027
• US$152 million bond exchange offer and exit consent solicitation
• Adlai Nortye Ltd. (NASDAQ: ANL) in its approximately US$100 million IPO on the Nasdaq
• OrbusNeich Medical Group in its US$62 million IPO and listing on the Hong Kong Stock Exchange
• Haitong International Capital Limited and CCB International Capital Limited as joint sponsors, and other underwriters in the IPO and listing of Huafang Group Inc. on the Hong Kong Stock Exchange
• CICC and China Industrial Securities in the US$64 million top-up share placement and subscription for C&D International
• Pharmaron in:
• approximately US$588 million dual primary listing and H share offering in Hong Kong
• Regulation S private offering of US$600 million of zero coupon convertible bonds due 2026
• approximately US$171 million placing of new H shares under general mandate
• BNP Paribas, China Construction Bank International, Industrial and Commercial Bank of China International and other underwriters in the spin-off and approximately US$126 million listing of Central China Management Company Limited on the Hong Kong Stock Exchange
• Shanghai Kindly Medical Instrument Co., Ltd., in its US$106 million IPO and listing on the Hong Kong Stock Exchange
• Viva Biotech (1873.HK) in its HK$1,521.5 million (approximately US$194 million) IPO and listing on the Hong Kong Stock Exchange
• Shanghai Haohai Biological (6826.HK) in its US$300 million IPO and listing on the Hong Kong Stock Exchange
• China Kanghui Holdings (NYSE: KH) in its US$78.7 million IPO and listing on the NYSE
• Montage Technology Group Limited (NASDAQ: MONT) in its US$81.7 million IPO and listing on NASDAQ
• LifeTech Scientific Corporation (8122.HK) in its HK$283 million IPO and listing on the Hong Kong Stock Exchange
• Christine International Holdings Ltd. (1210.HK) in its HK$400 million IPO and listing on the Hong Kong Stock Exchange
• China Lifestyle Food & Beverages Group Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• GCL-Poly Energy Holdings Ltd. in its IPO and listing on the Hong Kong Stock Exchange
• Giant Interactive Group Inc. in its follow-on offering on the New York Stock Exchange

M&A and Going Private

• Tantti Laboratory Inc. in its agreement to be acquired by Repligen Corporation
• Pharmaron in:
• US$118.7 million acquisition of Allergan Biologics Limited from AbbVie, Inc.
• US$137.5 million acquisition of US-based Absorption Systems
• US$30 million seed round investment in AccuGen Group
• Sundia Meditech Group in its US$80 million sale to a consortium led by Advent International Corporation
• the three founders of Nanjing USA, Inc. in the US$150 million trade sale to Roo Hsing Co., Ltd., a Taiwan listed company
• eHi Car Services Co., Ltd. (NYSE: EHIC) in its US$937.5 million management buyout transaction
• the two founders of Adicon Holdings Limited in a sale of 66% share of the company to a consortium comprised of the Chinese-listed company Meinian Onehealth Healthcare, funds managed by the Caryle Group, and four Carlyle co-investors
• Giant Interactive Group Limited in its privatization
• Montage Technology Group Limited in its privatization
• China Kanghui Medical in its acquisition by Medtronic